Abbott Laboratories (NYSE:ABT) Passes the Caviar Cruise Quality Investing Screen

The Caviar Cruise stock screening method is a structured way to find companies that show the signs of quality investing. This approach looks for businesses with good past performance, high profitability, sound finances, and the capacity to produce steady cash flow. The aim is to identify enterprises suitable for a long-term buy-and-hold plan, as their lasting competitive edges and effective operations are anticipated to build shareholder value over many years. The screen uses a multi-part group of filters to separate companies that are not only doing well now but also show the traits needed for continued success.

Abbott Laboratories (NYSE:ABT) appears as a strong candidate from this strict screening process. The global healthcare company works across four main segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its varied product range and operations in more than 160 countries offer a steady base for lasting growth, addressing fundamental needs in the worldwide healthcare field.

Meeting the Core Quality Criteria

Abbott Laboratories satisfies or goes beyond the main levels set by the Caviar Cruise screen, showing a notable mix of growth, profitability, and financial control.

• Revenue & EBIT Growth: The company has a 5-year revenue CAGR of 7.13%, above the screen's 5% minimum. More significantly, its EBIT growth of 8.41% is higher than its revenue growth. This is an important quality sign, as it points to better operational effectiveness and pricing ability, implying the company gains from economies of scale as it grows.
• High Return on Capital: Abbott’s Return on Invested Capital (excluding cash, goodwill, and intangibles) is a notable 19.79%, much higher than the 15% target. A high ROIC is a fundamental part of quality investing, showing management's skill in producing good profits from the capital put into the business.
• Sound Financial Health: The company displays notable financial strength, with a Debt-to-Free Cash Flow ratio of 1.98. This means Abbott could pay off all its debt in under two years using its present cash flow, meeting the screen's firm requirement of below 5. This low ratio offers good financial flexibility and lowers risk.
• High-Quality Earnings: Abbott’s 5-year average Profit Quality—which gauges the change of net income into free cash flow—is 99.60%. This almost perfect figure, above the 75% level, shows that the company’s reported profits are supported by real cash generation, a main indicator of earnings dependability and a business model that uses fewer assets.

Fundamental Analysis Overview

A close fundamental analysis of Abbott Laboratories supports the results from the screen. The company gets a good overall rating of 7 out of 10, with specific high points in profitability and financial health.

• Profitability: Abbott gets an 8 here, with high-performing numbers including a Profit Margin of 32.43% and an ROE of 27.65%, both placing in the best group of its industry competitors. Its margins have improved over recent years.
• Health: The company scores an 8 for financial health, backed by a solid Altman-Z score and the very good Debt-to-FCF ratio mentioned before, pointing to minimal solvency risk.
• Valuation & Growth: The valuation score of 4 shows a market price that is generally similar to the S&P 500, trading at a comparable P/E ratio. While not cheap, this is common for high-caliber companies. The growth score of 5 is backed by a quickening EPS growth rate and positive analyst views for future revenue and earnings growth.

A Fit for the Quality Investing Philosophy

Beyond the measurable numbers, Abbott Laboratories fits the non-quantitative parts of quality investing. The company works in the stable healthcare industry, which is aided by long-term population trends like aging societies. Its varied product range across diagnostics, medical devices, and nutrition establishes several growth sources and competitive benefits. The business is fairly simple to grasp and has a record of skilled management, traits that quality investors look for in a long-term holding.

For investors wanting to use this method for other possible options, the Caviar Cruise screen is a useful beginning. You can view the current results of this screen here.

---

Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation to buy, sell, or hold any security, or an endorsement of any investment strategy. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.